Pharmaceutical Economics and Policy
Moving in JAMA, Annals of Internal Medicine, medRxiv, Nature Biotechnology, Nature Genetics.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Pharmaceutical Economics and Policy
Newest first · last 60 days
Formulary rejections of single-source branded drugs increased by 67.4% from 2018 to 2024, leading to delayed or absent treatment in over half of initial rejection cases.
- Open access
Medicaid could save billions by adopting Most-Favored-Nation pricing, with potential reductions exceeding current rebates for prescription drugs.
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4